We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+12.76%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$478M
AUM Growth
+$56.7M
(+13%)
Cap. Flow
+$17.4M
Cap. Flow
% of AUM
3.64%
Top 10 Holdings %
Top 10 Hldgs %
53.49%
Holding
96
New
7
Increased
25
Reduced
16
Closed
12
Avg Time Held
7.8
quarters
Top 10 Avg Time Held
4.5
quarters
Top 20 Avg Time Held
7.7
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Theravance Biopharma
TBPH
|
+$13M |
| 2 |
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
|
+$6.09M |
| 3 |
OTIC
Otonomy, Inc.
OTIC
|
+$4.6M |
| 4 |
Translate Bio, Inc. Common Stock
TBIO
|
+$2.98M |
| 5 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$2.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Protalix BioTherapeutics
PLX
|
+$5.37M |
| 2 |
AtriCure
ATRC
|
+$2.69M |
| 3 |
Alector
ALEC
|
+$2.57M |
| 4 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$2.36M |
| 5 |
AGTC
Applied Genetic Technologies Corporation
AGTC
|
+$2.18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.51% |
| 2 | Miscellaneous | 2.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Stereotaxis
STXS
$104M
| $132M | 27.58% |
13,680,554
| – | – |
2013 Q2
32 quarters
|
|
2
Fate Therapeutics
FATE
$234M
| $27.3M | 5.71% |
314,360
| – | – |
2019 Q2
8 quarters
|
|
|
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $19.1M | 3.99% |
510,756
-77,000
| -13% | -$2.36M |
2018 Q2
12 quarters
|
|
4
DELISTED
Blueprint Medicines
BPMC
| $18.3M | 3.82% |
207,911
| – | – |
2016 Q4
18 quarters
|
|
|
5
DELISTED
Theravance Biopharma
TBPH
| $10.6M | 2.22% |
732,345
+691,180
| +1,679% | +$13M |
2021 Q1
1 quarter
|
|
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $10.4M | 2.18% |
181,467
| – | – |
2020 Q4
2 quarters
|
|
|
7
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $10.4M | 2.17% |
376,993
+151,600
| +67% | +$2.98M |
2020 Q3
3 quarters
|
|
8
DELISTED
Sage Therapeutics
SAGE
| $9.68M | 2.02% |
170,306
-11,000
| -6% | -$778K |
2017 Q4
14 quarters
|
|
9
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $9.13M | 1.91% |
94,100
+500
| +0.5% | +$40.6K |
2018 Q2
12 quarters
|
|
10
DexCom
DXCM
$31.8B
| $9.03M | 1.89% |
84,552
| – | – |
2017 Q3
15 quarters
|
|
11
DELISTED
Affimed
AFMD
| $8.2M | 1.72% |
96,486
-2,500
| -3% | -$228K |
2019 Q4
6 quarters
|
|
|
ARNA
12
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $8.16M | 1.71% |
119,615
+42,900
| +56% | +$2.8M |
2018 Q1
13 quarters
|
|
13
Nurix Therapeutics
NRIX
$2.58B
| $8.13M | 1.7% |
306,320
| – | – |
2021 Q1
1 quarter
|
|
14
Xenon Pharmaceuticals
XENE
$3.28B
| $7.57M | 1.58% |
406,535
| – | – |
2015 Q3
23 quarters
|
|
|
15
AtriCure
ATRC
$2.93B
| $7.26M | 1.52% |
91,529
-37,000
| -29% | -$2.69M |
2013 Q2
32 quarters
|
|
16
Neurocrine Biosciences
NBIX
$13.7B
| $7.17M | 1.5% |
73,655
| – | – |
2016 Q1
21 quarters
|
|
17
IDEAYA Biosciences
IDYA
$3.28B
| $6.96M | 1.46% |
331,661
| – | – |
2020 Q3
3 quarters
|
|
18
ProQR Therapeutics
PRQR
$207M
| $6.96M | 1.45% |
1,031,880
-68,120
| -6% | -$439K |
2017 Q4
14 quarters
|
|
19
iShares Biotechnology ETF
IBB
$10.4B
| $6.69M | 1.4% |
40,900
+500
| +1% | +$77K |
2016 Q4
18 quarters
|
|
20
Revolution Medicines
RVMD
$41.8B
| $6.66M | 1.39% |
209,731
+58,500
| +39% | +$2.04M |
2020 Q4
2 quarters
|
|
|
CSII
21
DELISTED
Cardiovascular Systems, Inc.
CSII
| $6.38M | 1.34% |
149,700
| – | – |
2018 Q2
12 quarters
|
|
|
FSTX
22
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $6.14M | 1.28% |
+714,285
| New | +$6.09M |
2021 Q2
0 quarters
|
|
23
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $6.04M | 1.26% |
53,000
+5,000
| +10% | +$584K |
2020 Q1
5 quarters
|
|
24
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.91B
| $5.35M | 1.12% |
77,675
+2,500
| +3% | +$191K |
2015 Q3
23 quarters
|
|
|
OTIC
25
DELISTED
Otonomy, Inc.
OTIC
| $5.31M | 1.11% |
2,379,392
+1,989,800
| +511% | +$4.6M |
2019 Q4
6 quarters
|
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q2 2021 Portfolio in Review
As of Q2 2021, DAFNA Capital Management held 96 positions worth $478M, up 13% from $421M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
DAFNA Capital Management deployed $17.4M of net new capital in Q2 2021, opening 7 new positions and adding to 25 existing holdings. Its largest new stake was F-star Therapeutics, Inc. Common Stock: 714,285 shares worth $6.14M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was AtriCure, an estimated $2.69M trimmed.
- DAFNA Capital Management's largest Q2 2021 buy was F-star Therapeutics, Inc. Common Stock: 714,285 shares worth $6.14M.
- DAFNA Capital Management added most to Theravance Biopharma in Q2 2021, an estimated $13M increase.
- DAFNA Capital Management's biggest Q2 2021 reduction was AtriCure, cutting an estimated $2.69M.
- DAFNA Capital Management fully exited Protalix BioTherapeutics in Q2 2021, selling an estimated $5.37M.
- DAFNA Capital Management's ten largest holdings make up 53% of its $478M portfolio in Q2 2021.
- DAFNA Capital Management opened 7 new positions and closed 12 in Q2 2021.
- DAFNA Capital Management's portfolio value rose 13% quarter-over-quarter to $478M.
Based on DAFNA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.